Answers are grounded in this paper and cite their sources.
In vivo pharmacokinetics are often evaluated in only one variation of an infection model, and the resulting exposures are assumed to be similar in each model. We evaluated and compared the effect of lung infection and immune status on the murine pharmacokinetics and pulmonary disposition of tedizolid and linezolid. Both factors resulted in differing blood and pulmonary exposure profiles, with similar trends for tedizolid and linezolid. These data highlight the importance of pharmacokinetic confirmation in each model.
No takes yet. Share an insight, caveat, or question.
Keel et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: